Development of a novel Bruton’s tyrosine kinase inhibitor that exerts anti-cancer activities potentiates response of chemotherapeutic agents in multiple myeloma stem cell-like cells

Despite recent improvements in multiple myeloma (MM) treatment, MM remains an incurable disease and most patients experience a relapse. The major reason for myeloma recurrence is the persistent stem cell-like population. It has been demonstrated that overexpression of Bruton’s tyrosine kinase (BTK)...

Descripción completa

Detalles Bibliográficos
Autores principales: Elbezanti, Weam Othman, Al-Odat, Omar S., Chitren, Robert, Singh, Jaikee Kumar, Srivastava, Sandeep Kumar, Gowda, Krishne, Amin, Shantu, Robertson, Gavin P., Nemmara, Venkatesh V., Jonnalagadda, Subash C., Budak-Alpdogan, Tulin, Pandey, Manoj K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9500300/
https://www.ncbi.nlm.nih.gov/pubmed/36160379
http://dx.doi.org/10.3389/fphar.2022.894535

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9500300/
https://www.ncbi.nlm.nih.gov/pubmed/36160379
http://dx.doi.org/10.3389/fphar.2022.894535

Ejemplares similares